Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

JA Ortiz

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Anatomy

Gastric Mucosa

Procedures

Concepts & Ideas

Disorders

Stomach Ulcer

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
19
Sacristán, A
11
Villamayor, F
10
Romero, A
8
Albet, C
6
Grau, MT
6
Márquez, M
6
Torres, J
5
Herrero, E
5
Fillat, O
4
Palop, D
4
Márquez, M
4
Agut, J
3
Conejo, L
3
Castelló, JM
3
Herrero, E

Sign-in to see all Coauthors

Publications

TOP 3
Palacín C; Tarragó C; Ortiz J A
Sertaconazole: pharmacology of a gynecological antifungal agent.
Agut J; Ortiz J A; Wurtman R J
Cytidine (5')diphosphocholine modulates dopamine K(+)-evoked release in striatum measured by microdialysis.
Martínez C; Albet C; Agúndez J A; Herrero E; Carrillo J A; Márquez M; Benítez J; Ortiz J A
Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of JA Ortiz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2000: Palacín C; Tarragó C; Ortiz J A
Sertaconazole: pharmacology of a gynecological antifungal agent.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2000;71 Suppl 1():S37-46.
2000: Agut J; Ortiz J A; Wurtman R J
Cytidine (5')diphosphocholine modulates dopamine K(+)-evoked release in striatum measured by microdialysis.
Annals of the New York Academy of Sciences 2000;920():332-5.
1999: Martínez C; Albet C; Agúndez J A; Herrero E; Carrillo J A; Márquez M; Benítez J; Ortiz J A
Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
Clinical pharmacology and therapeutics 1999;65(4):369-76.
1998: Bolós J; Anglada L; Gubert S; Planas J M; Agut J; Príncep M; De la Fuente N; Sacristán A; Ortiz J A
7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602).
Journal of medicinal chemistry 1998;41(27):5402-9.
1998: Palacin C; Tarragó C; Ortiz J A
In vitro activity of sertaconazole against Malassezia furfur and pachydermatis in different culture media.
Methods and findings in experimental and clinical pharmacology 1998;20(6):451-5.
1998: Albet C; Pérez A; Rozman E; Sacristan A; Ortiz J A
Pharmacokinetics of Camonagrel in experimental animal: rat, rabbit and dog.
European journal of drug metabolism and pharmacokinetics 1998;23(2):251-4.
1998: Romero A; Villamayor F; Rives A; Grau M T; Sacristán A; Ortiz J A
Twenty-four-month oral carcinogenicity study of ebrotidine in rats.
Teratogenesis, carcinogenesis, and mutagenesis 1998;18(6):263-77.
1997: Arredondo Y; Moreno-Mañas M; Pleixats R; Palacín C; Raga M M; Castelló J M; Ortiz J A
Preparation, antimicrobial evaluation, and mutagenicity of [2-hydroxyaryl]-[1-methyl-5-nitro-1H-2-imidazolyl]methanols , [5-tert-butyl-2-methylaminophenyl]-[1-methyl-5-nitro-1H-2-imidazo lyl]me thanol, and [2-hydroxyaryl]-[1-methyl-5-nitro-1H-2-imidazolyl] ketones.
Bioorganic & medicinal chemistry 1997;5(10):1959-68.
1997: Konturek P C; Brzozowski T; Konturek S I; Márquez M; Torres J; Ortiz J A
Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
Arzneimittel-Forschung 1997;47(4A):578-89.
1997: Popiela T; Kulig J; Karcz D; Tabor J; Torres J; Márquez M; Fillat O; Herrero E; Ortiz J A
Efficacy of ebrotidine and ranitidine combined with amoxicillin and metronidazole in the eradication of Helicobacter pylori in patients with duodenal ulcer.
Arzneimittel-Forschung 1997;47(4A):573-7.
1997: Puscas I; Puscas C; Coltau M; Pasca R; Torres J; Márquez M; Herrero E; Fillat O; Ortiz J A
Comparative study of the safety and efficacy of ebrotidine versus ranitidine and placebo in the prevention of piroxicam-induced gastroduodenal lesions.
Arzneimittel-Forschung 1997;47(4A):568-72.
1997: Puscas I; Puscas C; Coltau M; Torres J; Márquez M; Herrero E; Fillat O; Ortiz J A
Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers.
Arzneimittel-Forschung 1997;47(4A):565-8.
1997: Gedliczka O; Bobrzynski A; Rembiasz K; Fillat O; Torres J; Herrero E; Márquez M; Camps F; Ortiz J A
Efficacy of ebrotidine and ranitidine in the treatment of benign gastric ulcer.
Arzneimittel-Forschung 1997;47(4A):560-4.
1997: Matov V; Metchkov G; Krastev Z; Tchernev K; Mitova R; Márquez M; Torres J; Herrero E; Fillat O; Ortiz J A
Ebrotidine versus ranitidine in the treatment of acute duodenal ulcer. A multicentre, randomized, double-blind, controlled clinical trial.
Arzneimittel-Forschung 1997;47(4A):555-9.
1997: Muñoz-Navas M; Honorato J; Reina-Ariño M; Márquez M; Herrero E; Villamayor F; Torres J; Roset P N; Fíllat O; Camps F; Ortiz J A
Continuous intragastric pH monitoring in the evaluation of ebrotidine, cimetidine and placebo on gastric acidity in healthy volunteers.
Arzneimittel-Forschung 1997;47(4A):539-44.
1997: Albet C; Pérez J A; Rozman E; Márquez M; Herrero E; Ortiz J A
Pharmacokinetics of ebrotidine in healthy volunteers. A summary.
Arzneimittel-Forschung 1997;47(4A):535-9.
1997: Frías J; Esteban C; Carcas A J; Sánchez-García P; Albet C; Torres J; Márquez M; Ortiz J A
Pharmacokinetic study of ebrotidine administered in multiple doses to healthy volunteers for 4 days.
Arzneimittel-Forschung 1997;47(4A):531-4.
1997: Farré M; Roset P N; Badenas J M; Ugena B; Márquez M; Albet C; Herrero E; Ortiz J A
Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses.
Arzneimittel-Forschung 1997;47(4A):528-30.
1997: Romero A; Gómez F; Villamayor F; Ballesta A; Sacristán A; Ortiz J A
Comparative study of plasma gastrin levels in rats after two months of ebrotidine administration.
Arzneimittel-Forschung 1997;47(4A):524-7.
1997: Romero A; Gómez F; Villamayor F; Sacristán A; Ortiz J A
Study of the population of antral G-cells and enterochromaffin-like cells in the rat and mouse gastric mucosa after long-term treatment with ebrotidine.
Arzneimittel-Forschung 1997;47(4A):520-3.
1997: Romero A; Rives A; Grau M T; Villamayor F; Sacristán A; Ortiz J A
Carcinogenicity studies on ebrotidine.
Arzneimittel-Forschung 1997;47(4A):515-9.
1997: Romero A; Grau M T; Villamayor F; Sacristán A; Ortiz J A
Toxicity of ebrotidine on reproduction. Toxicity on fertility and general reproductive performance, embryo-fetal toxicity and peri- and postnatal toxicity.
Arzneimittel-Forschung 1997;47(4A):504-10.
1997: Romero A; Grau M T; Villamayor F; Sacristán A; Ortiz J A
Chronic toxicity of ebrotidine in rats and dogs.
Arzneimittel-Forschung 1997;47(4A):498-504.
1997: Romero A; Grau M T; Villamayor F; Sacristán A; Ortiz J A
Subacute toxicity of ebrotidine in rats and dogs.
Arzneimittel-Forschung 1997;47(4A):492-7.
1997: Grau M T; Romero A; Villamayor F; Sacristán A; Ortiz J A
Acute toxicity studies of ebrotidine.
Arzneimittel-Forschung 1997;47(4A):490-1.
1997: Rozman E; Albet C; Sacristán A; Ortiz J A
Metabolism of ebrotidine. A review.
Arzneimittel-Forschung 1997;47(4A):486-9.
1997: Albet C; Pérez J A; Sacristán A; Ortiz J A
Pharmacokinetics of ebrotidine in rats and dogs.
Arzneimittel-Forschung 1997;47(4A):483-5.
1997: Palacín C; Tarragó C; Sacristán A; Ortiz J A
In vitro anti-Helicobacter pylori activity of ebrotidine.
Arzneimittel-Forschung 1997;47(4A):471-4.
1997: Palop D; Conejo L; Sacristán A; Ortiz J A
Involvement of endogenous nitric oxide and sulfhydryl compounds in ebrotidine-induced gastroprotection.
Arzneimittel-Forschung 1997;47(4A):468-71.
1997: Romero A; Villamayor F; Palop D; Falcó J; Sacristán A; Ortiz J A
Study on the increment of the amount of gastric mucus in rats after repeated-dose administration of ebrotidine.
Arzneimittel-Forschung 1997;47(4A):455-8.
1997: Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz J A
Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Arzneimittel-Forschung 1997;47(4A):450-4.
1997: Agut J; Sánchez J C; Sacristán A; Ortiz J A
Action of ebrotidine, ranitidine and cimetidine on the specific binding to histamine H1- and H2-receptors.
Arzneimittel-Forschung 1997;47(4A):447-9.
1997: Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz J A
Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
Arzneimittel-Forschung 1997;47(4A):439-46.
1997: Albet C; Fernández J M; Castelló J M; Sacristán A; Ortiz J A
Physicochemical properties, analytical determinations and stability of ebrotidine.
Arzneimittel-Forschung 1997;47(4A):435-8.
1997: Anglada L; Raga M; Márquez M; Sacristán A; Castelló J M; Ortiz J A
Synthesis and assessment of formamidines as new histamine H2-receptor antagonists.
Arzneimittel-Forschung 1997;47(4A):431-4.
1997: Ortiz J A
Ebrotidine. A new generation H2-receptor antagonist and gastroprotective agent. Introduction.
Arzneimittel-Forschung 1997;47(4A):427-30.

Sign-in to see more